Australian medical device company Navi Medical Technologies has raised $A6.8 million to bring its neonatal catheter-placement system to US hospitals. The funding round, led by venture capital firm KP Rx with a $A4 million investment, follows FDA clearance and clinical trials at two leading children’s hospitals. Commercial sales are expected to begin this year.
The Neonav ECG Tip Location System addresses a critical challenge in neonatal and pediatric intensive care: accurate placement and monitoring of central venous access devices. These catheters deliver nutrition, fluids, and medications to the smallest and most fragile patients. Misplacement or migration of a catheter can cause serious harm, including damage to the heart or surrounding tissues, and can be fatal in neonates.
Traditional neonatal care relies heavily on X-ray confirmation to verify catheter position because existing technologies were not designed for the unique anatomy and physiology of newborns. Adult patients in the US benefit from ECG-guided catheter placement as a standard practice, but that approach has not been adapted effectively for infants until now. Navi’s technology fills that gap by combining real-time ECG guidance with ongoing migration surveillance throughout the device’s use.
The Technology and Its Clinical Advantage
Neonav uses real-time intravascular ECG to guide the placement of the catheter tip and monitor its position over time. This approach extends beyond conventional ECG tip location systems used in adult care. The system can reassess catheter position continuously, giving clinicians visibility into whether the catheter has shifted during treatment, a capability that has potential to improve patient safety while reducing the need for repeat imaging.
Alex Newton, CEO of Navi Medical Technologies, emphasized that neonatal and pediatric clinicians have relied on tools never intended for their smallest patients. The Neonav represents a fundamental shift toward technology designed from the start for neonatal anatomy and care requirements.
Regulatory Clearance and Expanded Indications
Navi achieved a significant regulatory milestone in 2025 when the FDA granted 510(k) clearance for Neonav, enabling the company to enter the US market. That clearance was followed in 2026 by an expanded FDA indication for use, extending Neonav’s approved applications to include umbilical venous catheters and additional vascular access procedures.
The 2026 expansion broadened the technology’s scope considerably. Neonav now carries the broadest indications for use among paediatric and neonatal vascular access systems, covering all central venous access devices and procedures within its cleared applications. This expanded regulatory clearance strengthens the company’s commercial opportunity by addressing more patient populations and clinical scenarios.
Clinical evaluations commenced at two leading US children’s hospitals following the initial FDA clearance. Those trials provided real-world evidence of the technology’s safety and efficacy in the hands of neonatal clinicians.
Capital Deployment and Commercial Timeline
The $A6.8 million raise will fund three key areas: manufacturing expansion, building a US commercial team, and launching the Neonav into leading children’s hospitals. Hashan De Silva, partner at lead investor KP Rx, stated that Navi had reached an important commercial inflection point. The company closed existing investors in the round as well, with Innovation Victoria and New Zealand- and Melbourne-based Pacific Channel participating.
Navi is headquartered in Melbourne and Boston, positioning the company to serve both its home market and the world’s largest healthcare economy. The US pediatric hospital market represents the primary commercial target, with clinical evaluations already underway at top-tier institutions.
Commercial sales are expected to commence in 2026, marking the transition from clinical validation to market adoption. This timeline depends on successful completion of ongoing hospital evaluations and the company’s ability to train hospital staff on the new technology.
Market Need and Clinical Outcome Implications
Central venous access is one of the most challenging procedures in neonatal and pediatric intensive care. The procedure itself carries inherent risk, and the consequences of error are severe. Reducing catheter misplacement and migration through real-time ECG guidance has the potential to prevent serious adverse events and reduce the imaging burden on vulnerable patients.
Repeat X-ray imaging in neonatal care carries cumulative radiation exposure risk, particularly concerning in patients who may require multiple imaging confirmations during prolonged hospitalization. A technology that reduces imaging needs while improving placement accuracy addresses two clinical concerns simultaneously.
Navi’s expanded FDA indication in 2026 reflects clinical and regulatory confidence in the technology’s breadth of application. The company now covers not only standard central venous catheters but also umbilical venous catheters, the most common first-line access route in emergency neonatal care.
The funding raise and commercial timeline signal that Navi has moved past the proof-of-concept phase. The company is now positioned to scale manufacturing and build the commercial infrastructure needed to distribute Neonav across the US pediatric hospital network. Whether the technology achieves rapid adoption at leading hospitals will determine whether this inflection point translates into sustainable commercial success.
